Coronary Artery Disease
Boston Scientific announces long-term data from the EVOLVE Trial of the SYNERGY™ Stent presented today at EuroPCR 2016 - May 19, 2016
Final, 5-year results from the EVOLVE Trial evaluating the Boston Scientific (NYSE: BSX) SYNERGY Stent support long-term safety and efficacy for the treatment of patients with de novo coronary artery disease...
New data presented at EuroPCR 2015 demonstrate strong performance of the SYNERGY™ Bioabsorbable Polymer stent System over four years - May 19, 2015
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System ...
New data from EVOLVE clinical program demonstrate SYNERGY™ bioabsorbable polymer stent meets key performance endpoints - Nov 19, 2014
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System...
SEE ALL PRESS RELEASES
